# Rezolute Inc. Common Stock (NV) (RZLT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.58, market value $441 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Rezolute Inc. Common Stock (NV) reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.1×**. The shares trade at 4.1× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -45.9%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 26.3%**. Earnings per share rose 26.3%.

## Financial health
- **Debt to equity: 0.09**. Debt is 0.09 times equity: a conservative balance sheet.
- **Current ratio: 14.37** (quick 14.37). Current assets cover the next year's liabilities 14.37 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Rezolute Inc. Common Stock (NV) does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover Rezolute Inc. Common Stock (NV); the consensus is buy, with an average price target of $7.67 (+67% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -37.9%** (YTD 94.1%, 3-mo 7.8%). The shares are down 37.9% over twelve months including dividends.
- **From 52-week high: -60.0%** (328.0% above the low). Trading 60% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 0.93** (volatility 127%). Beta of 0.93 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RZLT · Page: https://foliofundamentals.com/stocks/rzlt

Not investment advice.